Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Small Cell Lung Carcinoma 1Primary Myelofibrosis 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1

Interventions

ruxolitinib 9Peripheral Blood Stem Cell Transplantation 6Azacitidine 5Methotrexate 4Busulfan 4fludarabine phosphate 3Cyclosporine 3Whole-Body Irradiation 2Tacrolimus 2Mycophenolic Acid 2Cytarabine 2Antilymphocyte Serum 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2venetoclax 1vatalanib 1tagraxofusp 1sonidegib 1rucaparib 1pomalidomide 1pevonedistat 1pelcitoclax 1lestaurtinib 1givinostat hydrochloride 1givinostat 1fedratinib 1ethanolamine oleate 1axatilimab 1abiraterone 1Vitamin E 1Trimethoprim, Sulfamethoxazole Drug Combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Primary Myelofibrosis × INCB059872 × Clear all
NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
116 enrolled 36 charts
MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡